Biosimilar Substitution Could Rely On Electronic Medical Records
Pharmacy notification of physicians about substitution of interchangeable biosimilars is floated by a group of brand and generic firms, but opponents of the proposal suggest it is being pushed by companies that plan to use sales forces to market their biosimilars.
You may also be interested in...
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.
Stakeholder meeting will address poor enrollment rates and other issues that undermine the utility of pregnancy registries, as well as the use of alternatives, such as case control studies and claims-based database studies.